Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:41:24.414Z.
Calculation as of: 2026-10-06T15:41:24.414Z.
Quote observation: 2026-10-06T15:40:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
PE RATIO
N/A
Market Cap
$603.31M
PE Ratio
4.78
TTM Avg
17.55
3Y Avg
51.19
5Y Avg
25.53
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $641.60M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $647.51M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $651.65M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $631.26M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.10M | 114.93 | 37.43 | 206.22 | 206.22 |
| AngioDynamics, Inc. (ANGO)vs › | $610.27M | N/A | 43.31 | 43.31 | 89.76 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $676.50M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $603.31M | 4.78 | 17.55 | 51.19 | 25.53 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $596.86M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $685.97M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$11.20
Forward EPS (Est.)
$-0.79
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
